Want to see AEON full AI Analyst Report?
AEON Stock Chart & Stats
$1.10
-$0.02(-9.37%)
At close: 4:00 PM EST
$1.10
-$0.02(-9.37%)
Day’s Range― - ―
52-Week Range$0.51 - $1.45
Previous CloseN/A
Volume17.80M
Average Volume (3M)273.24K
Market Cap
$18.92M
Enterprise Value$4.35M
Total Cash (Recent Filing)$6.24M
Total Debt (Recent Filing)$2.63M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 18, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.03
Shares Outstanding26,307,210
10 Day Avg. Volume605,674
30 Day Avg. Volume273,237
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.63
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-229.00
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$16.30M
Bulls Say, Bears Say
Bulls Say
Cost ManagementR&D expenses declined 50.8% YoY to $4.4M, which were below the estimate, indicating effective cost management.
Regulatory ApprovalAeon finds alignment with the FDA on key biosimilar pathway requirements, boosting confidence in potential regulatory approval.
Bears Say
Funding UncertaintyGiven the uncertainty in funding, the price target is adjusted to $5 from $6, reflecting potential financial challenges.
Production DependencyAeon relies on Daewoong to manufacture ABP-450, and any production issues with Daewoong could adversely impact Aeon.
AEON Biopharma News
AEON FAQ
What was AEON Biopharma’s price range in the past 12 months?
AEON Biopharma lowest stock price was $0.51 and its highest was $1.45 in the past 12 months.
What is AEON Biopharma’s market cap?
AEON Biopharma’s market cap is $18.92M.
When is AEON Biopharma’s upcoming earnings report date?
AEON Biopharma’s upcoming earnings report date is Aug 18, 2026 which is in 47 days.
How were AEON Biopharma’s earnings last quarter?
AEON Biopharma released its earnings results on May 14, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.44 by $0.15.
Is AEON Biopharma overvalued?
According to Wall Street analysts AEON Biopharma’s price is currently Overvalued.
Does AEON Biopharma pay dividends?
AEON Biopharma does not currently pay dividends.
What is AEON Biopharma’s EPS estimate?
AEON Biopharma’s EPS estimate is -0.33.
How many shares outstanding does AEON Biopharma have?
AEON Biopharma has 26,307,210 shares outstanding.
What happened to AEON Biopharma’s price movement after its last earnings report?
AEON Biopharma reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.44. Following the earnings report the stock price went down -9.988%.
Which hedge fund is a major shareholder of AEON Biopharma?
Currently, no hedge funds are holding shares in AEON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AEON Biopharma
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Technical Analysis
Imunon
―
XTL Biopharmaceuticals Sponsored ADR
―
Aptorum Group
―
―
TransCode Therapeutics
―
Ownership Overview
45.76% Insiders
0.55% Mutual Funds
9.85% Other Institutional Investors
43.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---